$~

* **IN THE HIGH COURT OF DELHI AT NEW DELHI**

\+ W.P.(C) 16270/2024, CM APPL. 68486/2024, CM APPL. 4866/2025, CM APPL. 17120/2025, CM APPL. 26450/2025

MISS KIARA RAWAT THROUGH MRS. LOVELY GUSAIN .....Petitioner

Through: Mr. Vikas Singh, Sr. Advocate along with Mr. Varun Singh, Ms. Bhumi Sharma, Ms. Vasudha Singh, Ms. Deepika Kalia, Mr. Sudeep and Md. Atif Ahmad, Advocates.

versus

UNION OF INDIA & ORS. .....Respondents

Through: Mr. N. Venkataraman, ASG along with Mr. Kushagra Kansal, SPC and Mr. Rudra Paliwal, GP for UOI.
Mr. Ripudaman Bhardwaj, CGSC for UOI.
Mr. Rajiv Kapur, SC for SBI and Mr. Akshit Kapur, AOR for R-4 (SBI).
Mr. Tanveer Oberoi, Advocate for AIIMS.

CORAM:
HON'BLE MR. JUSTICE SACHIN DATTA

ORDER

% **28.10.2025**

1. The present petition has been filed the petitioner (through her parent), an infant (born on 03.02.2024) diagnosed with Spinal Muscular Atrophy (SMA) Type 1 on 25.07.2024, a rare and life threatening genetically inherited degenerative neuro muscular disease, which progressively weakens the muscles used for movement, swallowing and breathing.

2. The potential life-saving treatment for the said disease is one-time

intravenous infusion (injection) of Zolgensma, a gene therapy developed by a Swiss pharmaceutical company known as Novartis, specifically for children below the age of two with SMA. The said therapy is neither presently approved nor manufactured in India, but can be imported from USA with a doctor's recommendation and government's approval/s.

3. Unfortunately, despite the petitioner having a recommendation letter dated 30.07.2024 from the Chairperson and Senior Consultant of Sir Ganga Ram Hospital, New Delhi and a letter dated 17.08.2024 from AIIMS, Delhi (a Centre of Excellence as per the National Policy for Rare Disease, 2021), recommending for import and administration of Zolgensma, owning to the exorbitant cost of procurement (amongst the most expensive ones in the world, with a single dose costing approximately Rs.17.50 crores), parents of the petitioner are unable to import the said drug for treatment.

4. It is noticed that as far back as in July 2017, the Ministry of Health and Family Welfare, Government of India, formulated a National Policy for Treatment of Rare Diseases (NPTRD, 2017). The implementation of the policy, however, faced certain challenges and was consequently kept in abeyance *vide* a non-statutory Gazette Notification dated 18.12.2018. Subsequently, an expert committee was constituted in November 2018 to review the NPTRD 2017. Based on the report of the Expert Committee and with the approval of the competent authority, a draft National Policy for Rare Diseases was finalised and placed in the public domain on 13.01.2020 to invite comments/views from the stakeholders, general public, organisations and States/Union Territories.

5. Eventually, the National Policy for Rare Diseases, 2021 (hereinafter *"NPRD 2021"*) came to be formulated w.e.f. 30.03.2021. Notably,

paragraph 10 of the NPRD, 2021 provides as under:

> ***"10. Government of India support in treatment***
> *The following initiatives shall be taken for patients of Rare Diseases: Financial support upto Rs. 20 lakh under the Umbrella Scheme of Rashtriya Arogaya Nidhi shall be provided by the Central Government for treatment, of those rare diseases that require a one-time treatment (diseases listed under Group 1). Beneficiaries for such financial assistance would not be limited to BPL families, but extended to about 40% of the population, who are eligible as per norms of Pradhan Mantri Jan Arogya Yojana, for their treatment in Government tertiary hospitals only.*
>
> *ii. State Governments can consider supporting patients of such rare diseases that can be managed with special diets or hormonal supplements or other relatively low cost interventions (Diseases listed under Group 2).*
>
> *iii. Keeping in view the resource constraints, and a compelling need to prioritize the available resources to get maximum health gains for the community/population, the Government will endeavour to create alternate funding mechanism through setting up a digital platform for voluntary individual and corporate donors to contribute to the treatment cost of patients of rare diseases.*
>
> ***iv. Voluntary crowd-funding for treatment***
>
> *Keeping in view the resource constraint and competing health priorities, it will be difficult for the Government to fully finance treatment of high cost rare diseases. <u>The gap can however be filled by creating a digital platform for bringing together notified hospitals where such patients are receiving treatment or come for treatment, on the one hand, and prospective individual or corporate donors willing to support treatment of such patients.</u> The notified hospitals will share information relating to the patients, diseases from which they are suffering, estimated cost of treatment and details of bank accounts for donation/ contribution through online system. Donors will be able to view the details of patients and donate funds to a particular hospital. This will enable donors from various sections of the society to donate funds, which will be utilized for treatment of patients suffering from rare diseases, especially those under Group 3. <u>Conferences will be organised with corporate sector companies to motivate them to donate generously through digital platform. Ministry of Corporate Affairs will be requested to encourage PSUs and corporate houses to contribute as per the Companies Act as well as the provisions of the Companies (Corporate Social Responsibility Policy) Rules, 2014 (CSR Rules).</u>*

> *Promoting healthcare including preventive health care is included in the list in the Schedule for CSR activities.*
>
> *Treatment cost of the patient will be first charge on this fund. Any leftover fund after meeting treatment cost can be utilized for research purpose also."*

6. By way of an Office Memorandum (OM) dated 19.05.2022 (hereinafter "OM dated 19.05.2022") a cap of Rs.20,00,000/- (Rupees Twenty Lakhs only) as stipulated in paragraph 10(i) of the NPRD, 2021 was increased to Rs.50,00,000/- (Rupees Fifty Lakhs only). The said OM reads as under:

> *"OFFICE MEMORANDUM*
>
> *The undersigned is directed to state that the following provisions envisaged under Para 10(i) of National Policy of Rare Diseases (NPRD), 2021:*
>
> *"Financial Support upto Rs. 20 Lakh under the Umbrella Scheme of Rashtriya Arogaya Nidhi shall be provided by the Central Government for treatment, of those rare diseases that require a one-time treatment (diseases listed under Group 1). Beneficiaries for such financial assistance would not be limited to BPL families, but extended to about 40% of the population, who are eligible as per norms of Pradhan Mantri Jan Arogya Yojana, for their treatment in Government tertiary hospitals only."*
>
> *May be treated as replaced with the following:*
>
> *"Financial support upto Rs.50 lakhs shall be provided to the patients suffering from any category of Rare Diseases. The financial support will be provided to the patients for the treatment in any of the Centre of Excellence (CoE) mentioned in NPRD-2021, outside the Umbrella Scheme of Rashtriya Arogaya Nidhi."*
>
> *2. All other provisions of the policy will remain unchanged.*
>
> *3. These amendments come into effect from the date of issue of this Office Memorandum.*
>
> *4. The guidelines/procedure for providing financial assistance to the patients as per amended provisions are being finalized. However, till the*

> *finalization of guidelines and in order to provide uninterrupted and enhanced financial assistance i.e. upto Rs. 50 lakhs to the patients of rare diseases irrespective of category of disease, funds may continued to be granted from the current budget head of Umbrella Scheme of Rashtriya Arogya Nidhi (RAN).*
>
> *5. This issue with the approval of the competent authority."*

7. It is noticed that in consonance with paragraph 10(iv) of the NPRD, 2021, and in continuation of the aforementioned OM/notification dated 19.05.2022, the Ministry of Health and Family Welfare, Government of India *vide* notification dated 11.08.2022 bearing File No. 11037/40/2022-Grants (RD) issued "Guidelines and procedures for financial assistance for patients suffering from rare diseases". It was, *inter-alia*, notified as under: -

> *"To*
> *The Directors/Nodal Officers,*
> *All the Centres of Excellence*
> *(as per list attached)*
>
> *Sub: Guidelines and Procedures for giving financial to the patient suffering from various Rare Diseases.*
>
> *Madam/Sir,*
>
> *In continuation of this Ministry's O.M. of even number dated 19.05.2022 (copy enclosed), I am directed to inform that the Guidelines and Procedures for giving financial assitance to the patients suffering from various Rare Diseases have been approved by the Competent Authority. The same are enclosed herewith for further necessary action.*
>
> *-Sd-*
> *Manish Raj*
> *Under Secretary to*
> *the Government of*
> *India*
>
> *xxx xxx xxx*
>
> *2.3 Through Crowdfunding*

> *(i) Keeping in view the resource constraint and compelling health priorities, it will be difficult for the Government to fully finance the treatment of high cost rare diseases. The gap will be filled up by providing financial assitance through crowdfunding. A crowdfunding portal http://rarediseases.nhp.gov.in has already been created for receiving such fund.*
>
> *(ii) The CoEs will share information relatign to the patients, diseases from which they suffering and estimated cost of treatment on the crowdfunding portal.*
>
> *(iii) The fund received through crowdfunding will be used primarily for the treatment of the patients suffering from rare diseases. Any leftover fund after meeting treatment cost can be utilized for reasearch purposes also.*
>
> *(iv) CoEs have option to explore the possibility of gettiing financial assistance from other agencies/drugs manufacturers/ Corporate Sector under CSR by signing of MoU.*
>
> *The content of the MoU may be finalized by the Committee of the COE and approved by the Director of the COE."*

8. During the course of proceedings, it transpires that a digital Crowd Funding Platform (https://rarediseases.mohfw.gov.in/) has been operationalised in consonance with the NPRD, 2021 read with OMs dated 19.05.2022 and 11.08.2022. However, it has been pointed out by the learned counsel on behalf of the petitioner that as per the publicly available data, the said platform has not been successful in garnering sufficient amount of funds.

9. It is also noticed that a coordinate Bench of this Court in ***Master Arnesh Shaw vs. Union of India and Ors.,*** 2024 SCC OnLine Del 7114 (dated 04.10.2024) issued certain comprehensive and overarching directions as regards the steps to be taken by the Union of India, Pharmaceutical companies and National Rare Diseases Committee [formulated pursuant to the order dated 15.05.2020 passed in ***Master Arnesh Shaw*** (supra)],

pursuant to the NPRD, 2021. However, Ministry of Health and Family Welfare, Government of India contending that some of the directions passed in ***Master Arnesh Shaw*** (supra) were neither in consonance with the NPRD, 2021 nor appeared to be implementable, preferred SLP (C) 28777/2024 against the aforementioned judgment.

10. The Supreme Court *vide* order dated 09.12.2024, stayed the operation of the said judgment. However, the stay was subject to the Union of India complying with the terms and conditions stipulated under the notification/OM bearing File no. W-11037/40/2020-Grants (RD) dated 19.05.2022, issued by the Rare Disease Cell, MoHFW, Government of India.

11. It is the common case of respective counsel that the NPRD, 2021 continues to operate and the Union of India has been undertaking certain steps to effectuate and realise the purposes of the said policy, *inter alia*, by way of direction/s issued *vide* the OM dated 19.05.2022.

12. Attention of this Court is drawn to a communication dated 09.05.2025, issued on behalf of the Department of Public Enterprise (DPE), Ministry of Finance, Government of India. In terms thereof, the concerned Deputy Director communicated DPE's approval for setting up a committee under the Ministry of Health and Family Welfare, Government of India, as under: -

> *"Sir*
>
> *The Department of Public Enterprises (DPE) had already written to all CPSEs on 28th October 2022, forwarding the DO letter dated 30th September 2022 from the Secretary, Department of Health & Family Welfare, for sensitizing PSUs to undertake activities related to persons suffering from rare diseases and to consider the request of the Secretary, MoHFW while identifying activities for CSR spending. Copies of the*

> *aforementioned communications are enclosed.*
> *Further, DPE has no objection to the setting up of the proposed Committee under the ambit of the Ministry of Health & Family Welfare.*
>
> *Regards*
>
> *Kailash Bhandari*
> *Deputy Director*
> *DPE"*

13. In furtherance of the aforesaid communication, *vide* order dated 16.05.2025 passed in the present proceedings, it was *inter-alia* recorded as under: -

> *"1. Learned Standing Counsel appearing for the Union of India (respondent no. 1) submits that the Department of Public Enterprises (DoPT) had written to all CPSEs on 28th October, 2022, forwarding the DO letter dated 30th September 2022 from the Secretary, Department of Health & Family Welfare, for sensitizing PSUs to undertake activities related to persons suffering from rare diseases and to consider the request of the Secretary, MoHFW while identifying activities for CSR spending.*
>
> *2. He further submits that DoPT has no objection for formation of a committee for raising funds for the petitioner's treatment as well as for the treatment of similarly situated children. It is acceded that the said committee shall raise funds from PSUs, government entities and private donors, as contemplated under the National Policy for Rare Diseases, 2021, under the heading of voluntary crowd-funding.*
>
> *3. Respective counsel for the parties are directed to offer their suggestions as to the composition of the said committee to be constituted."*

14. However, it is noticed that for some inexplicable reason/s the comments/views set out in the aforesaid email dated 09.05.2025 has sought to be withdrawn by the Joint Director, DPE *vide* a subsequent email dated 24.07.2025 (copy of which has been handed over by learned CGSC). The same reads as under:

> *"Reference trailing email*
> *The view of DPE, duly approved by Secretary (DPE) are as under:*

> *CSR activities of corporates including Central Public Sector Enterprises (CPSEs) are governed as per Section 135 of Companies Act, 2013 which inter-alia prescribes the criteria for companies falling under the ambit of CSR, activities covered under CSR and the amount to be allocated for CSR activities.*
>
> *The Companies Act, 2013 is administered by the Ministry of Corporate Affairs. After consultations with the Ministry of Corporate Affairs, DPE has already written to all CPSEs on 28th October, 2022 forwarding the DO letter dated 30th September 2022 from Secretary, Department of Health & Family Welfare for sensitizing PSUs for undertaking activities related to persons suffering from rare diseases and to consider the request of Secretary, MoHFW while identifying activities for CSR spending.*
>
> *Since CSR is a Board driven activity as per provisions of the Companies Act, 2013 and DPE has already sensitized the CPSEs as requested by MoHFW, setting up of a Committee to inter-alia collect and manage CSR funds of CPSEs may not be required.*
>
> *Further, the earlier comments views/comments furnished vide DPE email dated 9th May 2025 may be treated as withdrawn.*
>
> *Kailash Bhandari*
> *Joint Director*
> *Department of Public Enterprises*
> *Tel: 011-24366247*
> *Mob: 9891239669"*

15. Attention is also drawn to an OM dated 09.06.2025, passed by the Ministry of Corporate Affairs, Government of India (MoCA) whereby, it has been reiterated that Corporate Social Responsibility (CSR) is a Board driven process and the same are monitored, planned and executed by the Board of the concerned company on recommendation of its CSR Committee and MoCA has no role to play in suggesting the same. The said O.M reads as under: -

> *"OFFICE MEMORANDUM*
>
> *Sub: Instruction in W.P.(C) No. 16270 of 2024 (Miss Kiara Rawat through Mrs. Lovely Gusain vs. UOI & Ors.) pending in High Court of Delhi – Reg.*

> *The undersigned is directed to invite the reference of MoHFW's e-mail dated 15.05.2025 on the subject cited above and to say that the said point i.e. (ii) indicated vide aforesaid E-Mail dated 15.05.2025, does not pertain to this Ministry. Further, it is informed that this Ministry provides broad framework for Corporate Social Responsibility (CSR) through Section 135 of the Companies Act, 2013 ('Act'), Schedule VII of the Act and the Companies (CSR Policy) Rules 2014. The Schedule VII of the Act indicates areas or subjects that can be undertaken by companies as eligible CSR activities. It is also informed that CSR is a board driven process and board of the company is empowered to plan, decide, execute and monitor the CSR activities of the company based on the recommendation of its CSR committee. Furthermore, there is no role of this ministry of recommendations of any activity by CSR Committee/Board of companies*
>
> *2. This is issued with the approval of the competent authority.*
>
> *(Shikha Garg)*
> *Deputy Director,*
> *CSR-Cell"*

16. Further, the respondent no.1, through written submissions dated 31.07.2025 and 21.08.2025, has apprised this Court of various initiatives undertaken by the Ministry of Health and Family Welfare, Government of India, for the implementation and advancement of the NPRD, 2021, particularly as regards the Crowd Funding Platform. The same reads as under: -

> *"The initiative has been actively promoted through outreach activities. The few activities undertaken in this regard are briefed as under:*
>
> > *a. A high-level webinar was held on 17.06.2021 under the chairmanship of the then Hon'ble Union Minister for Health and Family Welfare with representatives from line Ministries, industry associations, PSUs, and other stakeholders to sensitize them about the rare diseases and the need for Voluntary donations for the treatment of patients with Rare Diseases in accordance with the provisions under Section 10(iv) of NPRD, 2021.*

b. MoHFW vide OM dated 09.07.2021 and DO letter dated 13th June, 2022 requested Ministry of Corporate Affairs (MOCA) to include the subject "Donation for Rare Diseases" in Schedule VII of the Companies Act, 2013 so as to enable the PSUs and the corporates to contribute through Corporate Social Responsibility (CSR) fund of the companies. However, MoCA vide OM dated 27.08.2021 mentioned that item no. (i) of Schedule VII already includes 'promoting health care including preventive health care' and under this head, the companies can undertake activities related to treatment of patients suffering from rare diseases subject to compliance of the provisions of CSR Rules and guidelines issued thereunder from time to time.

c. Thereafter, Secretary (Health) wrote to Secretary, Department of Public Enterprises (DPE), M/o Finance, GoI to seek support to sensitize the PSUs and corporate regarding mobilization of funds for rare diseases under CSR so as to enable them to donate for this important social cause.

d. A National Symposium on Rare Diseases was organized in collaboration with WHO-India at Udaipur on Feb 29 & Mar 1, 2024 wherein eminent experts from Centers of Excellence as well as academia, Officers from MoHFW, DHR, CDSCO, DBT, State Nodal Officers, Patient Groups participated. In this symposium, among others, vaious issues including promoting awareness about Rare Diseases among PSEs to encourage CSR funding, 'were discussed.

e. Department of Public Enterprises, M/o Finance, GoI has also organized an Interactive Regional Workshop on capacity building of CPSES on 29th Feb, 2024 in Varanasi with focus on the identified CSR sub-theme which included "Screening of Rare Diseases".

f. The Department of Public Enterprises (DPE) had also written to all CPSEs on 28th October 2022 for sensitizing PSUs to undertake activities related to persons suffering from rare diseases and to consider the request of the Secretary, MoHFW while identifying activities for CSR spending.

g. The Centres of Excellence (CoEs) have been actively engaged in spreading awareness about the Crowdfunding Portal to ensure wider publicity and outreach. The publicity efforts have been undertaken through newspapers, social media handles of the CoEs, and their official websites. These initiatives aim to encourage

> *voluntary contributions from individuals, organizations, and philanthropic entities towards the treatment of patients suffering from rare diseases. By promoting the portal through multiple channels, the CoEs facilitate greater public participation and support for crowdfunding efforts, thereby complementing government initiatives in addressing the high cost of treatment for rare diseases. Screenshots of Newsclippings, Social Media Handles of CoEs are attached herewith for reference.*
>
> *h. In order to enhance awareness about rare diseases, provisions of NPRD and digital crowdfunding platform, a series of sensitization workshops on the theme of 'Care for Rare: Together We Win' have been conducted across the country to bring together key stakeholders, including healthcare professionals, patient groups, and representatives from various organizations. These workshops have been organized at 12 CoEs during January - February, 2025. Among the various important agendas discussed, a key focus was on creating awareness about the Crowdfunding Portal as a vital tool to mobilize voluntary contributions for the treatment of rare disease patients. These workshops served as an important platform to disseminate information, build understanding, and encourage collective efforts in addressing the challenges posed by rare diseases.*
>
> *i. In a meeting held with Centres of Excellence (CoEs) on 25.07.2025 under the Chairpersonship of Joint Secretary (RD), MoHFW, the representatives of some CoEs intimated that they have written letters to some PSUs and Companies with the request to offer CSR funding for rare disease patients sometimes ago. Moreover, the companies/PSUs are reluctant to offer the CSR funding due to their preference on building infrastructure over treatment of patients. They also highlighted the constraints in CSR rules of respective companies/PSUs. After detailed deliberation on the issue, the Chairperson directed that the Rare Disease Committee in all CoEs would take all measures for (i) updation of patient data on ICMR Rare Disease Registry and crowdfunding portal, (ii) promoting and regularly publicizing the crowdfunding portal, (iii) identification of and regular persuasion with potential donors/Companies/PSUs for voluntary donations/CSR funding for treatment of rare disease patients and (iv) encourage patient advocacy groups for soliciting crowd funding.*

In view of the reasons stated above, it is humbly submitted that the formation of the Committee may not be appropriate, as it is not within

> *the functions of the Government to directly raise funds from individuals or corporate entities.”*

17. This Court is in agreement with learned counsel for the Union of India that funding initiatives taken through CSR are monitored, planned and executed by the Board of concerned companies (Public Sector Undertakings) and no mandamus can be issued to any company/Public Sector Undertakings (PSUs) to earmark its CSR Funds for the purpose of providing treatment to the individuals suffering from rare diseases. However, it would certainly be desirable to sensitise the PSUs to undertake activities/initiatives relating to individuals suffering from rare diseases and to earmark CSR funds for the same. The same would be warranted in light of the fact that as per O.M. dated 27.08.2021, issued by the Ministry of Corporate Affairs, Government of India (as stated above) it has been clarified that the treatment of patients suffering from rare disease comes within the purview of item no.(i) of Schedule VII of the Companies Act, 2013 under the head “promoting health care including preventive health care”.

18. It is also noticed that the crowd funding platform set up by Ministry of Health and Family Welfare, Government of India has not met with the desired response and funds garnered thus far, have been quite meagre. As per the publicly available data, till date, for approximately 3981 patients registered, only a meagre amount of Rs.3,91,589/- has been collected on the said platform.

19. There can be no cavil with the inference that the Crowd Funding efforts undertaken by setting up of the Crowd Funding platform (https;//rarediseases.mohfw.gov.in/), is required to be supplemented by

vigorous efforts to garner funds including by way of channelization of CSR funds into Crowd Funding Platform.

20. Thus, in the aforesaid conspectus, the limited purpose of the present order is to ensure that suitable measures are taken to effectuate the purport of setting up of aforementioned Crowd Funding Platform and to ensure that sufficient resources can be augmented thereunder. The challenges faced by individuals suffering from rare diseases, are required to be seen through a prism of inclusion and humane lens; rather than being merely considered as a medical problem. Given the exorbitant cost involved in affording adequate treatment to those afflicted with rare disease and the resource constrains in allocating budgetary outlays for the same, it is imperative that all efforts be made to ensure that the innovative measure undertaken by the Government of India by setting up of voluntary Crowd Funding Platform, receives the success and results that it deserves.

21. In the above backdrop, the petitioner has put forth certain suggestions for the purpose of setting up of a committee to exercise an oversight of the Crowd Funding Platform already set up by the Ministry of Health and Family Welfare, Government of India and to ensure that maximum efforts are made to ensure that requisite amount of funds are funnelled into the Crowd Funding platform, including by way of CSR contributions.

22. While this Court is not inclined to accept the suggestions made by the learned counsel for the petitioner *in toto*, this Court is in an agreement that it would be salutary if a committee is set up comprising of senior officials from the Ministry of Health and Family Welfare and the Ministry of Corporate Affairs, Government of India along with expert/s in the field of rare diseases for the effective implementation and furtherance of the

aforesaid purpose.

23. In the above background, this Court finds it apposite to constitute a committee to supervise/oversee the operation of the Crowd Funding Platform operationalized by the Ministry of Health and Family Welfare, Government of India, as under:

i. The Committee shall comprise of the following members *viz.*:

a) Dr. Rajiv Bahl, Secretary, Department of Health Research, Ministry of Health and Family Welfare, Government of India and Director General, Indian Council of Medical Research as Chairperson of the Committee;

b) Dr. V.K. Paul, Member (Health), Niti Aayog, Government of India;

c) An officer at the level of Joint Secretary, MoCA, Government of India [who is in charge of overseeing implementation of the Companies (Corporate Social Responsibility Policy) Rules, 2014], to be nominated by the Secretary, MoCA; and

d) An officer at the level of Joint Secretary in the Department of Public Enterprises, Ministry of Finance, Government of India, to be nominated by the Secretary of the Department.

ii. the Committee shall take adequate steps to spread awareness as regards the existence and objective of aforesaid platform, with the aim to encourage potential donors to make contribution/s for the treatment of individuals suffering from rare diseases;

iii. an attempt shall be made to ensure that CSR funds are funnelled to the Crowd Funding Platform (https://rarediseases.mohfw.gov.in/). For the said purpose, the committee shall make an endeavour to reach out to

Public Sector Undertakings (PSUs) to sensitise them and encourage them to make voluntary contribution/s;

iv. the Committee shall also take steps to ensure that necessary action is taken in furtherance of and for effectuating the NPRD 2021, and to ensure that the outcomes contemplated thereunder are achieved to the maximum extent. For the aforesaid purpose, the Committee shall liaise with the concerned Ministries/Authorities and;

v. the Committee shall meet at least once month in the office of the Chairperson or as may be decided by the Committee.

24. Considering the facts and circumstances of the present case, it is hoped and expected that an endeavour shall be made, without causing prejudice to the rights of other similarly situated individuals, to utilize the funds raised under the supervision of the aforesaid Committee through the Crowd Funding Platform towards the medical treatment of the petitioner in the present petition.

25. Let the aforesaid Committee file a Status Report, through Mr. Ripudaman Bhardwaj, CGSC, within a period of 12 weeks from today.

26. List for further consideration on 22.12.2025.

SACHIN DATTA, J

OCTOBER 28, 2025/*sl*